Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan.

IF 5.5 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-03-05 DOI:10.1080/14760584.2024.2323133

Mitsuhiro Nagano, Kazumasa Kamei, Hiroyuki Matsuda, Chihiro Takahashi, Jingyan Yang, Koji Wada, Naohiro Yonemoto

{"title":"Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan.","authors":"Mitsuhiro Nagano, Kazumasa Kamei, Hiroyuki Matsuda, Chihiro Takahashi, Jingyan Yang, Koji Wada, Naohiro Yonemoto","doi":"10.1080/14760584.2024.2323133","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to evaluate the public health and economic impact of the COVID-19 booster vaccination with BNT162b2 in Japan during an Omicron-dominant period from early 2022.Research design and methods: A combined cohort Markov decision tree model estimated the cost-effectiveness of annual or biannual booster vaccination strategies compared to no booster vaccination for those aged 65 years and above, and those aged 60-64 years at high risk as the base case. The societal perspective was primarily considered. We also examined other target populations with different age and risk groups. Sensitivity and scenario analyses with alternative inputs were performed.Results: Annual and biannual vaccination strategies were dominant from the societal perspective in the base case. Incremental Cost Effectiveness Ratios (ICERs) from the payer perspective were JPY 1,752,499/Quality Adjusted Life Year (QALY) for annual vaccination and JPY 2,831,878/QALY for biannual vaccination, both less than the threshold value in Japan (JPY 5 million/QALY). The results were consistent even when examining other target age and risk groups. All sensitivity and scenario analyses indicated that ICERs were below JPY 5 million/QALY.Conclusions: Booster vaccination with the COVID-19 vaccine BNT162b2 is a dominant strategy and beneficial to public health in Japan.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"349-361"},"PeriodicalIF":5.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2323133","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study was to evaluate the public health and economic impact of the COVID-19 booster vaccination with BNT162b2 in Japan during an Omicron-dominant period from early 2022.

Research design and methods: A combined cohort Markov decision tree model estimated the cost-effectiveness of annual or biannual booster vaccination strategies compared to no booster vaccination for those aged 65 years and above, and those aged 60-64 years at high risk as the base case. The societal perspective was primarily considered. We also examined other target populations with different age and risk groups. Sensitivity and scenario analyses with alternative inputs were performed.

Results: Annual and biannual vaccination strategies were dominant from the societal perspective in the base case. Incremental Cost Effectiveness Ratios (ICERs) from the payer perspective were JPY 1,752,499/Quality Adjusted Life Year (QALY) for annual vaccination and JPY 2,831,878/QALY for biannual vaccination, both less than the threshold value in Japan (JPY 5 million/QALY). The results were consistent even when examining other target age and risk groups. All sensitivity and scenario analyses indicated that ICERs were below JPY 5 million/QALY.

Conclusions: Booster vaccination with the COVID-19 vaccine BNT162b2 is a dominant strategy and beneficial to public health in Japan.

查看原文本刊更多论文

日本 COVID-19 强化接种 BNT162b2 的成本效益分析。

背景：本研究的目的是评估自 2022 年初起，在日本的奥米克龙占主导地位期间，COVID-19 强化接种 BNT162b2 对公共卫生和经济的影响：综合队列马尔可夫决策树模型估算了每年或每半年加强接种疫苗策略与不加强接种疫苗相比的成本效益，以 65 岁及以上人群和 60-64 岁高风险人群为基础案例。我们主要从社会角度进行了考虑。我们还研究了不同年龄和风险群体的其他目标人群。我们还对其他输入数据进行了敏感性分析和情景分析：结果：从社会角度来看，在基础案例中，一年一次和一年两次的疫苗接种策略占主导地位。从支付方的角度来看，每年接种疫苗的增量成本效益比 (ICER) 为 1,752,499 日元/质量调整生命年 (QALY)，每半年接种疫苗的增量成本效益比 (ICER) 为 2,831,878 日元/质量调整生命年 (QALY)，均低于日本的临界值（500 万日元/质量调整生命年）。即使在研究其他目标年龄组和风险组时，结果也是一致的。所有的敏感性和情景分析表明，ICER 都低于 500 万日元/QALY：结论：使用 COVID-19 疫苗 BNT162b2 进行加强接种是一种主要策略，对日本的公共卫生有益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.